SynthesisClinical and translational science2026
Temporal Patterns of Outcomes After DMARD Tapering or Withdrawal in Rheumatoid Arthritis With Sustained Disease Control: A Systematic Review and Meta-Analysis.
Synthesis in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) requires lifelong treatment with disease-modifying antirheumatic drugs (DMARDs). In patients with sustained disease control, DMARD de-escalation has been proposed to lessen treatment burden, but its efficacy and safety remain elusive. We conducted a systematic review and meta-analysis of randomized controlled trials evaluating DMARD tapering or withdrawal in controlled RA. PubMed, Embase, and the Cochrane Library were searched to January 16, 2026. The primary outcome was disease flare, and secondary outcomes included radiographic progression and adverse events (AEs). Risk ratios (RRs) were pooled using Mantel-Haenszel models. Prespecified subgroup analyses were conducted by DMARD class and follow-up duration. In total, 27 publications comprising 5262 participants were included. Any DMARD tapering increased flare risk overall (RR 1.56, 95% CI 1.26-1.98), mainly driven by the biologic DMARD (bDMARD) subgroup, with increased flare risk observed < 9 months (RR 1.61, 95% CI 1.13-2.31), but not at longer follow-up (> 9 months). In contrast, any DMARD withdrawal substantially increased flare risk (RR 2.23, 95% CI 1.83-2.94), primarily driven by the bDMARD subgroup across all follow-up durations (< 9 months, 9-18 months, and > 18 months). Both tapering (weak evidence) and withdrawal (strong evidence) promoted radiographic progression at 9-18 months and > 18 months. Neither tapering nor withdrawal reduced AEs. In conclusion, DMARD tapering, particularly of bDMARDs, should be considered cautiously in controlled RA because of the increased flare risk, possible radiographic progression, without clear reduction in AEs. DMARD withdrawal should be generally avoided whenever possible.
trial registrationCRD420251066774 (PROSPERO).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.